Examiner: ANDERSON, REBECCA L

Tech Center 1600 • Art Units: 1626

This examiner grants 73% of resolved cases

Analysis

Rebecca L. Anderson, in Art Unit 1626 within Tech Center 1600, has resolved 1044 cases. The allowance rate is 73.4%, and the median days to allowance is 852. This indicates a favorable and relatively efficient prosecution path for applicants. The 852-day median pendency is notably faster than many other units, suggesting a streamlined process.

The interview lift is 23.6%, suggesting that interviews are very effective for this examiner. This lift can significantly boost the 73.4% base allowance rate, making personal engagement a key strategy for practitioners. With 1044 resolved cases, the data provides a very robust baseline for these statistics. Practitioners should consider the 23.6% lift as a tool to resolve rejections and potentially move the 852-day process toward a grant even more quickly. The 73.4% allowance rate is a strong indicator of success.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

73.4%

Allow Rate

+13.4% vs TC avg

1,095

Total Applications

+23.6%

Interview Lift

852

Avg Prosecution Days

Based on 1044 resolved cases, 2023–2026

Rejection Statute Breakdown

2.6%

§101 Eligibility

24.1%

§102 Novelty

18.8%

§103 Obviousness

32.8%

§112 Clarity

Currently Pending Office Actions

App #	Title	Status	Assignee
18569721	TREATMENT AND PREVENTION OF DEVELOPMENTAL DISORDERS AND MENTAL DISEASES	Non-Final OA	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA,
18532632	TREATMENT OF MYELOPROLIFERATIVE DISEASES AND DISORDERS WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN	Non-Final OA	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18288473	MELANIN MATERIALS FOR TISSUE REPAIR	Non-Final OA	Northwestern University
19296560	PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE	Final Rejection	Compass Pathfinder Limited
18552453	Ether-Linked Antiviral Compounds	Non-Final OA	Pfizer Inc.
18668678	ALLOSTERIC INHIBITOR OF WEE1 KINASE	Final Rejection	H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
18246263	PIPERAZINE-BASED CATIONIC LIPIDS	Final Rejection	TRANSLATE BIO, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy